Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Immuneering Q3 2026 Results: Net Loss of $24.2M, Loss Widens

Immuneering Corp is a late-stage clinical oncology company focused on developing its lead candidate, atebimetinib (IMM-1-104), for first-line pancreatic cancer. The company reports a history of significant net losses and expects to require substantial additional capital to fund its ongoing Phase 1/2a and MAPKeeper 301 registrational trials.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-24.2-15.0
EPS (diluted, $ a share)$-0.37$-0.38

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: IMRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Immuneering Corp: key numbers

Share price
$3.52Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Immuneering Corp

All →
4:16 PM ET 8-K
Leadership Change

Immuneering Leadership Change

Immuneering Corporation appointed Grant C. Bogle, MBA, to its Board of Directors as a Class III Director, effective November 9, 2026. Mr. Bogle will receive compensation under the company's standard non-employee director arrangements and has entered into a standard indemnification agreement.

Counterparty
Grant C. Bogle
4:12 PM ET 8-K
Financial Results

Immuneering Financial Results

Immuneering reported Q3 2026 financial results and provided updates on its clinical pipeline, including the extension of follow-up for its Phase 2 pancreatic cancer trial as patients are living longer than projected. The company also announced that enrollment for its pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule, allowing for an expanded enrollment target of 570 patients and a potential acceleration of the mid-2028 topline data readout.

“We are thrilled to share that follow-up in our Phase 2 trial in first-line pancreatic cancer is being extended because patients are living longer than projected. We now plan to provide an update on topline data from the atebimetinib + mGnP arm of that trial in the first half of 2027. We are also excited to report that enrollment in our pivotal Phase 3 MAPKeeper 301 trial is ahead of schedule. This strong momentum enables us to expand the enrollment target and potentially accelerate our expected mid-2028 topline data readout. We have updated our cash runway guidance to the fourth quarter of 2028 to reflect our Phase 2 extension, accelerated and expanded Phase 3 enrollment, and commercial readiness activities.”

Ben Zeskind, Ph.D., CEO of Immuneering

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.